Skip to content
Parakho

Gufic Biosciences Ltd

NSE GUFICBIOBSE 509079

Q1 FY27, unaudited

Revenue
₹260.82 Cr
Profit after tax
₹22.46 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations260.82+14.94%940.48
Other income0.46−48.84%2.58
Total income261.28+14.69%943.06
Employee benefit expense41.80+16.14%151.68
Finance costs9.32+0.92%36.61
Depreciation & amortisation7.71−0.17%30.83
Total expenses231.11+9.26%857.57
Profit before tax30.16+85.30%85.49
Tax expense7.70+83.21%22.34
Profit after tax22.46+86.03%63.15
Total comprehensive income22.46+86.03%63.65
Earnings per share
Earnings per share, basic₹2.24₹6.30
Earnings per share, diluted₹2.24₹6.30

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q1 FY27

Gufic Biosciences reported Q1 FY27 revenue of INR260.8 crores versus INR226.9 crores in Q1 FY26, with EBITDA margin expanding to 18.09% from 14.6%. Management discussed progress at the Indore facility including depot and microsphere suite completion, a CMO partnership with Hetero for semaglutide, and a shift in international markets from a distributor-led to a front-end model. Management also addressed capacity utilization trends at Indore and reiterated a growth commitment for the company overall.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 49 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 06 Oct 2026.